Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity.

ABSTRACT:

Importance

Concerns about the cardiovascular safety of recombinant human growth hormone (rhGH) treatment in childhood have recently been raised; however, long-term studies are limited.

Objective

To investigate the long-term risk of overall and severe cardiovascular events in patients previously treated with rhGH in childhood and whether there is an association with treatment duration or dose.

Design, setting, and participants

This nationwide population-based cohort study included patients treated with rhGH during childhood from January 1, 1985, to December 31, 2010, in Sweden, with follow-up through December 31, 2014. Included patients were treated with rhGH owing to isolated growth hormone deficiency (GHD), small for gestational age (SGA), and idiopathic short statur

SUBMITTER: Tidblad A 

PROVIDER: S-EPMC7754074 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature